| scholarly article | Q13442814 |
| P2093 | author name string | Atsunori Kashiwagi | |
| Yoshihiko Nishio | |||
| Hiroshi Maegawa | |||
| Shinji Kume | |||
| Katsutaro Morino | |||
| Satoshi Ugi | |||
| Yoshio Nagai | |||
| Osamu Sekine | |||
| Takeshi Yoshizaki | |||
| Yasuhiro Maeno | |||
| Masateru Ushio | |||
| P2860 | cites work | Insulin signalling and the regulation of glucose and lipid metabolism | Q24292020 |
| Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway | Q24316367 | ||
| Glucose and cAMP regulate the L-type pyruvate kinase gene by phosphorylation/dephosphorylation of the carbohydrate response element binding protein | Q24555088 | ||
| Identification of the major intestinal fatty acid transport protein | Q28145772 | ||
| An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha | Q28294042 | ||
| Regulation of hepatic lipogenesis by the transcription factor XBP1 | Q28507784 | ||
| Mice with targeted disruption of the fatty acid transport protein 4 (Fatp 4, Slc27a4) gene show features of lethal restrictive dermopathy | Q28588298 | ||
| Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption | Q28593100 | ||
| Lipid homeostasis, lipotoxicity and the metabolic syndrome. | Q30383031 | ||
| NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease | Q33761680 | ||
| Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes | Q33878155 | ||
| Liver X receptors (LXR) as therapeutic targets in dyslipidemia | Q34014852 | ||
| New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c | Q34682304 | ||
| The role of peroxisome proliferator-activated receptor gamma coactivator-1 beta in the pathogenesis of fructose-induced insulin resistance. | Q35090215 | ||
| Short-term alterations in carbohydrate energy intake in humans. Striking effects on hepatic glucose production, de novo lipogenesis, lipolysis, and whole-body fuel selection | Q35768126 | ||
| Fasting and postprandial apolipoprotein B-48 levels in healthy, obese, and hyperlipidemic subjects | Q36045964 | ||
| Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c): two key regulators of glucose metabolism and lipid synthesis in liver | Q36055803 | ||
| Role of mitochondria in non-alcoholic fatty liver disease | Q36849037 | ||
| Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1-/- mice | Q36956106 | ||
| Postprandial dyslipidemia in insulin resistance: mechanisms and role of intestinal insulin sensitivity | Q37226212 | ||
| The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome | Q37724585 | ||
| Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. | Q38016566 | ||
| Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus | Q38319698 | ||
| Single nucleotide polymorphism (-468 Gly to A) at the promoter region of SREBP-1c associates with genetic defect of fructose-induced hepatic lipogenesis [corrected]. | Q38341737 | ||
| Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia | Q38343372 | ||
| Dephosphorylation of translation initiation factor 2alpha enhances glucose tolerance and attenuates hepatosteatosis in mice | Q39975807 | ||
| Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent | Q40762653 | ||
| Diabetes of the liver: the link between nonalcoholic fatty liver disease and HFCS-55. | Q42450828 | ||
| Ezetimibe ameliorates intestinal chylomicron overproduction and improves glucose tolerance in a diet-induced hamster model of insulin resistance. | Q42662009 | ||
| Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance | Q43298703 | ||
| Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-contain | Q44031791 | ||
| Rosiglitazone improves intestinal lipoprotein overproduction in the fat-fed Syrian Golden hamster, an animal model of nutritionally-induced insulin resistance | Q44890786 | ||
| Intestinal assembly and secretion of highly dense/lipid-poor apolipoprotein B48-containing lipoprotein particles in the fasting state: evidence for induction by insulin resistance and exogenous fatty acids | Q46475324 | ||
| Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome | Q46893987 | ||
| Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes | Q47915943 | ||
| Improved metabolic control reduces the number of postprandial apolipoprotein B-48-containing particles in type 2 diabetes. | Q51558513 | ||
| Alterations in apolipoprotein B-48 in the postprandial state in NIDDM. | Q51592590 | ||
| Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet | Q54659066 | ||
| P433 | issue | 2 | |
| P921 | main subject | steatosis | Q1365091 |
| P304 | page(s) | E293-304 | |
| P577 | publication date | 2013-05-28 | |
| P1433 | published in | American Journal of Physiology - Endocrinology and Metabolism | Q15765671 |
| P1476 | title | Ezetimibe prevents hepatic steatosis induced by a high-fat but not a high-fructose diet. | |
| P478 | volume | 305 |
| Q91789864 | A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis |
| Q33894773 | Acceleration of biliary cholesterol secretion restores glycemic control and alleviates hypertriglyceridemia in obese db/db mice |
| Q33839003 | Acute Effect of Metformin on Postprandial Hypertriglyceridemia through Delayed Gastric Emptying |
| Q64229466 | Alcohol Induces More Severe Fatty Liver Disease by Influencing Cholesterol Metabolism |
| Q45403785 | Current and emerging pharmacological therapy for non-alcoholic fatty liver disease |
| Q53803400 | Deep fried edible oils disturb hepatic redox equilibrium and heightens lipotoxicity and hepatosteatosis in male Wistar rats. |
| Q41006475 | Effect of anti-hyperlipidemia drugs on the alpha-tocopherol concentration and their potential for murine malaria infection |
| Q87327728 | Ezetimibe in the balance: can cholesterol-lowering drugs alone be an effective therapy for NAFLD? |
| Q37604513 | Ezetimibe markedly attenuates hepatic cholesterol accumulation and improves liver function in the lysosomal acid lipase-deficient mouse, a model for cholesteryl ester storage disease |
| Q34487963 | Ezetimibe prevents the development of non‑alcoholic fatty liver disease induced by high‑fat diet in C57BL/6J mice |
| Q33755566 | Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH) |
| Q37497908 | Phytosterols protect against diet-induced hypertriglyceridemia in Syrian golden hamsters. |
| Q38891202 | Quantitation of the rates of hepatic and intestinal cholesterol synthesis in lysosomal acid lipase-deficient mice before and during treatment with ezetimibe |
| Q34166185 | Three months of high-fructose feeding fails to induce excessive weight gain or leptin resistance in mice |
Search more.